Merck & Co., Inc. (MRK)
Why Merck (MRK) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
MRK Beats Q3 Earnings Estimates, Narrows 2025 Sales View, Stock Down
Merck tops Q3 earnings and revenue estimates on strong oncology, new drugs and animal health sales, while narrowing its 2025 revenue outlook.
Merck & Co., Inc. (MRK) Q3 2025 Earnings Call Transcript
Merck & Co., Inc. ( MRK ) Q3 2025 Earnings Call October 30, 2025 9:00 AM EDT Company Participants Peter Dannenbaum - Vice President of Investor Relations Robert Davis - Chairman, President & CEO Caroline Litchfield - Executive VP & CFO Dean Li - Executive VP & President of Merck Research Laboratories Conference Call Participants Asad Haider - Goldman Sachs Group, Inc., Research Division Geoffrey Meacham - Citigroup Inc., Research Division Akash Tewari - Jefferies LLC, Research Division Evan Seigerman - BMO Capital Markets Equity Research Daina Graybosch - Leerink Partners LLC, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Carter Gould - Cantor Fitzgerald & Co., Research Division Terence Flynn - Morgan Stanley, Research Division Umer Raffat - Evercore ISI Institutional Equities, Research Division Courtney Breen - Sanford C. Bernstein & Co., LLC.
Merck Q3 financial results top estimates, company lowers revenue guidance
Merck & Co Inc (NYSE:MRK, ETR:6MK) on Thursday reported third quarter 2025 earnings and revenue that surpassed Wall Street expectations, lifted by strong demand for its cancer immunotherapy Keytruda, but reduced its full-year sales outlook to reflect lower estimated tariff costs, among other factors. The pharmaceutical company's revenue for the quarter rose 4% year over year to $17.28 billion, exceeding the $16.96 billion analyst consensus estimate provided by LSEG.
Merck (MRK) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Merck (MRK) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Merck (MRK) Q3 Earnings and Revenues Beat Estimates
Merck (MRK) came out with quarterly earnings of $2.58 per share, beating the Zacks Consensus Estimate of $2.36 per share. This compares to earnings of $1.57 per share a year ago.
Merck tops estimates on Keytruda strength and narrows profit outlook, as it lowers estimated tariff hit
Merck reported third-quarter earnings and revenue that topped estimates in part due to strong demand for its cancer immunotherapy Keytruda, and narrowed its full-year profit outlook to reflect lower estimated tariff costs and other items. Sales of Keytruda topped more than $8 billion for the first time in a quarter, up 10% from the same period a year ago.
Merck posts higher third-quarter sales as Keytruda growth offsets drop from Gardasil
Merck & Co on Thursday posted higher third quarter revenue as growth from its blockbuster cancer drug Keytruda offset falling sales from human papillomavirus vaccine Gardasil in China.
Buy, Sell or Hold MRK Stock Ahead of Q3 Earnings? Things to Know
MRK faces pressure from weak vaccine sales and rising competition, but strong oncology growth and new launches could support a rebound.
Are You Looking for a High-Growth Dividend Stock?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes?
Merck's Non-Oncology Drugs Q3 Performance: What to Expect
MRK expects new products like Capvaxive, Winrevair, and the Animal Health business to support its top-line growth in the third quarter.
Merck breaks ground on $3B manufacturing plant in Virginia
Merck is breaking ground on a new 400,000-square-foot manufacturing facility in Elkton, Virginia, as part of its $70 billion U.S. investment strategy.
